Cover Image
市場調查報告書

Frontier Pharma:血液癌症的First-in-Class革新 - 細胞激素的信號傳達和激酶標的免疫療法優勢

Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

出版商 GBI Research 商品編碼 512859
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
Frontier Pharma:血液癌症的First-in-Class革新 - 細胞激素的信號傳達和激酶標的免疫療法優勢 Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline
出版日期: 2017年05月03日 內容資訊: 英文 84 Pages
簡介

本報告提供血液關於癌症相關調查分析,革新案例,概要,開發中產品的評估,計劃的評估,策略性整合等系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 革新案例

  • 生技藥品的機會擴大
  • 分子標的多樣化
  • 創新的First-in-Class產品 (劃時代的醫藥品)的開發現在也富有魅力
  • 法規、償付政策對First-in-Class產品的革新有利
  • 持續革新
  • 報告指南

第4章 臨床、商業性情形

  • 疾病概要
  • 症狀
  • 診斷
  • 病因
  • 病理生理學
  • 流行病學
  • 治療
  • 上市產品概要
  • 目前未滿足需求

第5章 開發平台形勢的評估

  • 血液癌症開發平台概要
  • First-in-Class、多用途的計劃

第6章 血液癌症的信號 (信號傳達) 網路與創新的調整

  • 信號傳達網路的複雜
  • 信號傳達途徑和First-in-Class分子標的整合
  • First-in-Class矩陣的評估

第7章 First-in-Class標的評估

第8章 策略性整合

  • 產業整體First-in-Class交易
  • 血液癌症的交易形勢
  • 授權交易
  • 共同開發交易
  • 參與/不參與事前交易First-in-Class開發平台計劃的清單

第9章 附錄

目錄
Product Code: GBIHC442MR

Executive Summary

Hematological cancer describes a group of malignancies that affect the blood, lymph nodes and bone marrow. The three main types are leukemia, lymphoma and myeloma. The American Cancer Society (ACS) predicts that in 2017 there will be almost 173,000 new cases of leukemia, lymphoma and myeloma together. Although individually accounting for relatively modest proportions of new cancer cases, when combined these hematological cancers are estimated to be the third most common type of cancer in the US. Furthermore, there are predicted to be over 58,000 deaths caused by hematological cancers in the US in 2017 (ACS, 2017).

Hematological cancers therapy area is relatively large, and is characterized by malignancies of the blood - specifically a proliferation of abnormal white blood cells, which subsequently has downstream effects on other blood and immune cells. There are three main types of hematological cancer: leukemia; lymphoma and myeloma. Leukemia is caused by a proliferation of abnormal white blood cells that impair the ability of the bone marrow to produce red blood cells and platelets. Lymphoma affects the lymphocytes of the lymphatic system, which collect in lymph nodes and other tissue and impair the immune system. Myeloma affects plasma cells and prevents the normal production of antibodies.

Hematological cancers pipeline is the largest within the oncology therapy area - with 1,474 programs in active development it accounts for over 19% of the therapy area. There are a total of 477 first-in-class pipeline programs in development for hematological cancers, representing 40% of those with a disclosed molecular target. Cytokine signaling targets make up the greatest proportion of pipeline and first-in-class programs, followed in both instances by kinases. These two target categories are intrinsically linked with components of immune response, and are responsible for the majority of targets in part due to the nature of hematological cancers and their action on immune cells. Additionally, much of the most promising potential within the hematological cancers area revolves around targeted immunotherapies.

Between 2006 and the beginning of 2017 a total of 467 licensing deals and 323 co-development deals were completed in the hematological cancers therapy area. Of those with a disclosed value, the combined aggregate deal value was $67.6 billion, highlighting that strategic consolidations within hematological cancers are particularly valuable. The high level of deal-making activity is also indicative of a strong willingness on the part of pharmaceutical companies to engage in strategic consolidations in order to mitigate some of the risks and the significant failure rates associated with drug development in the hematological cancers therapy area. Companies have a meaningful incentive to invest in pipeline programs due to the strong commercial performance of leading cancer products.

The report "Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline" assesses versatile and first-in-class innovation in the hematological cancer pipeline, highlighting key trends in first-in-class product distribution. Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry, with 477 first-in-class products.

In depth, this report provides the following -

  • Analyze the hematological cancers pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating hematological cancers.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
  • Visualize the composition of the hematological cancers market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
  • Helps to understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
  • Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of hematological cancer therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Scope

  • With 1,474 products in active development, the pipeline is considerably large. How will pipeline innovation affect the future hematological cancer market?
  • There are 477 first-in-class products in the hematological cancer pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
  • The majority of first-in-class products were identified to be in development for multiple indications. Are versatile products likely to play a key role in the future treatment of hematological cancer?
  • Analysis of the history of strategic consolidations revealed an increasing amount of deal activity and a large number of first-in-class products not yet involved in any deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Reasons to buy

  • Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
  • Visualize the composition of the hematological cancers market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
  • Analyze the hematological cancers pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating hematological cancers.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
  • Understand the level of versatility across the pipeline and within each molecular target. Assess the pipeline activity of each versatile first-in-class product and the indications that they are being developed for.
  • Identify commercial opportunities in the hematological cancers deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of hematological cancer therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Executive Summary

  • 2.1. Large Therapy Area with a High Degree of Pathophysiological Crossover
  • 2.2. High Degree of First-in-Class Programs and Program Versatility in a Strong Pipeline
  • 2.3. Sharp Increase in Deal Activity in Recent Years

3. The Case for Innovation in the Hematological Cancer Market

  • 3.1. Growing Number of Opportunities for Biologic Products
  • 3.2. Diversification of Molecular Targets
  • 3.3. Innovative First-in-Class Product Developments Remain Attractive
  • 3.4. Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
  • 3.5. Sustained Innovation
  • 3.6. GBI Research Report Guidance

4. Clinical and Commercial Landscape

  • 4.1. Disease Overview
  • 4.2. Symptoms
  • 4.3. Diagnosis
    • 4.3.1. Leukemia
    • 4.3.2. Lymphoma
    • 4.3.3. Myeloma
  • 4.4. Etiology
    • 4.4.1. Leukemia
    • 4.4.2. Lymphoma
    • 4.4.3. Myeloma
  • 4.5. Pathophysiology
    • 4.5.1. Leukemia
    • 4.5.2. Lymphoma
    • 4.5.3. Myeloma
  • 4.6. Epidemiology
    • 4.6.1. Leukemia
    • 4.6.2. Lymphoma
    • 4.6.3. Myeloma
  • 4.7. Treatment
    • 4.7.1. Surgery and Radiation Therapy
    • 4.7.2. Stem-Cell Transplantation
    • 4.7.3. Pharmacotherapy
  • 4.8. Overview of Marketed Products
  • 4.9. Current Unmet Need in the Hematological Cancer Market

5. Pipeline Landscape Assessment

  • 5.1. Hematological Cancers Pipeline Overview
    • 5.1.1. Pipeline Development Landscape
    • 5.1.2. Molecular Targets in the Pipeline
    • 5.1.3. Comparative Distribution of Programs between the Hematological Cancer Market and Pipeline by Molecular Target
  • 5.2. First-in-Class and Versatile Programs
    • 5.2.1. First-in-Class Hematological Cancers Programs by Phase, Molecule Type and Molecular Target
    • 5.2.2. Versatility of First-in-Class Pipeline Programs

6. Signaling Network and Innovation Alignment within Hematological Cancers

  • 6.1. Complexity of Signaling Networks in Hematological cancer
  • 6.2. Signaling Pathways and First-in-Class Molecular Target Integration
  • 6.3. First-in-Class Matrix Assessment

7. First-in-Class Target Evaluation

  • 7.1. Pipeline Programs Targeting Neurogenic Locus Notch Homolog Protein 1
    • 7.1.1. Overview of Pipeline Programs Targeting Neurogenic Locus Notch Homolog Protein 1
  • 7.2. Pipeline Programs Targeting Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR-1
    • 7.2.1. Overview of Pipeline Programs Targeting Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR-1
  • 7.3. Pipeline Programs Targeting Aurora kinase-A and -B
    • 7.3.1. Overview of Pipeline Programs Targeting Aurora Kinase-A and -B
  • 7.4. Pipeline Programs Targeting TNF Receptor Superfamily Member-6
    • 7.4.1. Overview of Pipeline Programs Targeting TNF Receptor Superfamily Member-6
  • 7.5. Pipeline Programs Targeting Leukocyte Surface Antigen CD47
    • 7.5.1. Overview of Pipeline Programs Targeting Leukocyte Surface Antigen CD47
  • 7.6. Pipeline Programs Targeting e3 Ubiquitin Protein Ligase MDM-2
    • 7.6.1. Overview of Pipeline Programs Targeting e3 Ubiquitin Protein Ligase MDM2
  • 7.7. Pipeline Programs Targeting Transforming Growth Factor-Beta Receptor Type-1
    • 7.7.1. Overview of Pipeline Programs Targeting Transforming Growth Factor-Beta Receptor Type-1
  • 7.8. Pipeline Programs Targeting Spleen Tyrosine Kinase
    • 7.8.1. Overview of Pipeline Programs Targeting Spleen Tyrosine Kinase
  • 7.9. Conclusion

8. Deals and Strategic Consolidations

  • 8.1. Industry-Wide First-in-Class Deals
  • 8.2. Hematological Cancer Deals Landscape
  • 8.3. Licensing Deals
    • 8.3.1. Deals by Region, Year and Value
    • 8.3.2. Deals by Stage of Development and Value
    • 8.3.3. Molecule Type and Value
    • 8.3.4. Molecular Target and Value
  • 8.4. Co-development Deals
    • 8.4.1. Deals by Region, Year and Value
    • 8.4.2. Deals by Stage of Development and Value
    • 8.4.3. Molecule Type and Value
    • 8.4.4. Molecular Target and Value
  • 8.5. List of First-in-Class Pipeline Programs with and without Prior Deal Involvement

9. Appendix

  • 9.1. Abbreviations
  • 9.2. References
  • 9.3. Research Methdology
    • 9.3.1. Data integrity:
    • 9.3.2. Innovative and meaningful analytical techniques and frameworks:
    • 9.3.3. Evidence based analysis and insight:
  • 9.4. Secondary Research
    • 9.4.1. Market Analysis
    • 9.4.2. Pipeline Analysis
  • 9.5. Contact Us
  • 9.6. Disclaimer

List of Tables

  • Table 1: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Epidemiology of Hematological Disease Severity, Forecast 2017
  • Table 2: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Commonly Used Chemotherapy Regimens, 2017
  • Table 3: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Receptor Neurogenic Locus Notch Homolog Protein 1 as a Molecular Target, 2017
  • Table 4: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR-1 as a Molecular Target, 2017
  • Table 5: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Aurora Kinase-A and -B as a Molecular Target, 2017
  • Table 6: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for TNF Receptor Superfamily Member-6 as a Molecular Target, 2017
  • Table 7: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Leukocyte Surface Antigen CD47 as a Molecular Target, 2017
  • Table 8: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Molecular Target e3 Ubiquitin Protein Ligase MDM2, 2017
  • Table 9: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Transforming Growth Factor-Beta Receptor Type-1 as a Molecular Target, 2017
  • Table 10: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Data for Spleen Tyrosine Kinase as a Molecular Target, 2017

List of Figures

  • Figure 1: Overall Pharmaceutical Industry, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Products Approvals (%), 1987-2015
  • Figure 2: Versatile Innovation in Hematological Cancers Therapeutics Market, First-in-Class and Non-First-in-Class Products, Sales Performance After Marketing Approval, 2006-2013 ($m)
  • Figure 3: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Marketed Product Overview, 2017
  • Figure 4: Pharmaceutical Market, Global, Developmental Pipeline Overview, 2017
  • Figure 5: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Pipeline by Stage of Development and Molecule Type, 2017
  • Figure 6: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Pipeline by Molecular Target, 2017
  • Figure 7: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Molecular Target Category Comparison, Pipeline and Marketed Products, 2017
  • Figure 8: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Pipeline for Hematological Cancers by Stage of Development and Molecule Type, 2017
  • Figure 9: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Pipeline by Molecular Target, 2017
  • Figure 10: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Molecular Target Family Comparison, Pipeline First-in-Class and Established Molecular Targets, 2017
  • Figure 11: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Percentage of First-in-Class Products in Pipeline by Stage of Development (%), 2017
  • Figure 12: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Percentage of First-in-Class Programs in Pipeline by Molecular Target (%), 2017
  • Figure 13: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Hematological Cancers Pipeline Products by Number of Indications, 2017
  • Figure 14: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Versatile Pipeline for Hematological Cancers by Stage of Development and Molecule Type, 2017
  • Figure 15: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Versatile Pipeline for Hematological Cancers by Molecular Target, 2017
  • Figure 16: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Pipeline for Hematological Cancers by Versatile Status and Molecular Target Class, 2017
  • Figure 17: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Pipeline for Hematological Cancers Indications, 2017 (Part - 1)
  • Figure 18: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Pipeline for Hematological Cancers Indications, 2017 (Part - 2)
  • Figure 19: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Pipeline for Hematological Cancers Indications, 2017 (Part - 3)
  • Figure 20: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Pipeline for Hematological Cancers Indications, 2017(Part - 4)
  • Figure 21: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix, 2017
  • Figure 22: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix, 2017
  • Figure 23: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix, 2017
  • Figure 24: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix, 2017
  • Figure 25: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting Neurogenic Locus Notch Homolog Protein 1, 2017
  • Figure 26: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR-1, 2017
  • Figure 27: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting Aurora Kinase-A and -B, 2017
  • Figure 28: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting TNF Receptor Superfamily Member-6, 2017
  • Figure 29: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting Leukocyte Surface Antigen CD47, 2017
  • Figure 30: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting e3 Ubiquitin Protein Ligase MDM2, 2017
  • Figure 31: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting Transforming Growth Factor-Beta Receptor Type-1, 2017
  • Figure 32: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Pipeline Programs Targeting Spleen Tyrosine Kinase, 2017
  • Figure 33: Pharmaceutical Market, Global, Industry-Wide Deals by Stage of Development, 2006-2014
  • Figure 34: Pharmaceutical Market, Global, Industry Licensing Deal Values by Stage of Development, 2006-2014
  • Figure 35: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2017
  • Figure 36: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Licensing Deals by Stage of Development, 2006-2017
  • Figure 37: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Licensing Deals by Molecule Type, 2006-2017
  • Figure 38: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Licensing Deals by Molecular Target, 2006-2017
  • Figure 39: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2017
  • Figure 40: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Co-development Deals by Region and Value, 2006-2017
  • Figure 41: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006-2017
  • Figure 42: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Co-development Deals by Molecule Type, 2006-2017
  • Figure 43: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2017
  • Figure 44: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2017
  • Figure 45: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Programs in Active Development Involved in Previous Deals, 2017 (Part - 1)
  • Figure 46: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Programs in Active Development Involved in Previous Deals, 2017 (Part - 2)
  • Figure 47: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Programs in Active Development Involved in Previous Deals, 2017 (Part - 3)
  • Figure 48: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Programs in Active Development Without Recorded Prior Deal Involvement, 2017(Part - 1)
  • Figure 49: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Programs in Active Development Without Recorded Prior Deal Involvement, 2017(Part - 2)
  • Figure 50: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Programs in Active Development Without Recorded Prior Deal Involvement, 2017(Part - 3)
  • Figure 51: Versatile Innovation in Hematological Cancers Therapeutics Market, Global, First-in-Class Programs in Active Development Without Recorded Prior Deal Involvement, 2017(Part - 4)
Back to Top